Minju Kim, Young Ho Park, Yoo Sung Song, Kyunghun Kang, Ki-Su Park, Shin Young Jeong, Sang-Woo Lee, Eunjeong Ji, SangYun Kim, Etsuro Mori
{"title":"有纹状体多巴胺能缺陷和无纹状体多巴胺能缺陷的NPH患者脑脊液抽头试验后步态改善:初步研究。","authors":"Minju Kim, Young Ho Park, Yoo Sung Song, Kyunghun Kang, Ki-Su Park, Shin Young Jeong, Sang-Woo Lee, Eunjeong Ji, SangYun Kim, Etsuro Mori","doi":"10.1212/CPJ.0000000000200549","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Recent studies have highlighted the occurrence of reduced striatal signal intensity on dopamine transporter (DAT) scans in patients with idiopathic normal pressure hydrocephalus (iNPH). The aim of our study was to investigate whether the extent of symptom improvement after a CSF tap test (TT) differs between iNPH patients with reduced striatal DAT uptake and those with normal uptake.</p><p><strong>Methods: </strong>We conducted gait analysis on 44 patients with iNPH who underwent DAT scans at Seoul National University Bundang Hospital (SNUBH) and Kyungpook National University Chilgok Hospital (KNUCH) both before and after a CSF TT. A positive response to the TT was defined as an improvement in walking speed of 10% or greater compared with baseline. We compared TT response rates between iNPH patients with and without striatal dopaminergic deficit using logistic regression models, with the medical institution (SNUBH, KNUCH) as a stratification variable.</p><p><strong>Results: </strong>Among 36 patients without striatal dopaminergic deficit, 22 patients (61.11%) exhibited a response after the TT, whereas among 8 patients with striatal dopaminergic deficit, 5 patients (62.5%) exhibited a response after the TT. The response rate after TT was not significantly different between the iNPH patients with and without striatal dopaminergic deficit (odds ratio 0.46; <i>p</i> value = 0.4048).</p><p><strong>Discussion: </strong>Our findings suggest that gait improvement after a CSF TT in patients with iNPH remains consistent regardless of the presence or absence of reduced striatal DAT uptake. Further research involving a larger cohort is necessary to validate these observations.</p>","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":"15 6","pages":"e200549"},"PeriodicalIF":3.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456307/pdf/","citationCount":"0","resultStr":"{\"title\":\"Gait Improvement Following CSF Tap Test in NPH Patients With and Without Striatal Dopaminergic Deficit: A Preliminary Study.\",\"authors\":\"Minju Kim, Young Ho Park, Yoo Sung Song, Kyunghun Kang, Ki-Su Park, Shin Young Jeong, Sang-Woo Lee, Eunjeong Ji, SangYun Kim, Etsuro Mori\",\"doi\":\"10.1212/CPJ.0000000000200549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Recent studies have highlighted the occurrence of reduced striatal signal intensity on dopamine transporter (DAT) scans in patients with idiopathic normal pressure hydrocephalus (iNPH). The aim of our study was to investigate whether the extent of symptom improvement after a CSF tap test (TT) differs between iNPH patients with reduced striatal DAT uptake and those with normal uptake.</p><p><strong>Methods: </strong>We conducted gait analysis on 44 patients with iNPH who underwent DAT scans at Seoul National University Bundang Hospital (SNUBH) and Kyungpook National University Chilgok Hospital (KNUCH) both before and after a CSF TT. A positive response to the TT was defined as an improvement in walking speed of 10% or greater compared with baseline. We compared TT response rates between iNPH patients with and without striatal dopaminergic deficit using logistic regression models, with the medical institution (SNUBH, KNUCH) as a stratification variable.</p><p><strong>Results: </strong>Among 36 patients without striatal dopaminergic deficit, 22 patients (61.11%) exhibited a response after the TT, whereas among 8 patients with striatal dopaminergic deficit, 5 patients (62.5%) exhibited a response after the TT. The response rate after TT was not significantly different between the iNPH patients with and without striatal dopaminergic deficit (odds ratio 0.46; <i>p</i> value = 0.4048).</p><p><strong>Discussion: </strong>Our findings suggest that gait improvement after a CSF TT in patients with iNPH remains consistent regardless of the presence or absence of reduced striatal DAT uptake. Further research involving a larger cohort is necessary to validate these observations.</p>\",\"PeriodicalId\":19136,\"journal\":{\"name\":\"Neurology. Clinical practice\",\"volume\":\"15 6\",\"pages\":\"e200549\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456307/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology. Clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1212/CPJ.0000000000200549\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200549","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Gait Improvement Following CSF Tap Test in NPH Patients With and Without Striatal Dopaminergic Deficit: A Preliminary Study.
Background and objectives: Recent studies have highlighted the occurrence of reduced striatal signal intensity on dopamine transporter (DAT) scans in patients with idiopathic normal pressure hydrocephalus (iNPH). The aim of our study was to investigate whether the extent of symptom improvement after a CSF tap test (TT) differs between iNPH patients with reduced striatal DAT uptake and those with normal uptake.
Methods: We conducted gait analysis on 44 patients with iNPH who underwent DAT scans at Seoul National University Bundang Hospital (SNUBH) and Kyungpook National University Chilgok Hospital (KNUCH) both before and after a CSF TT. A positive response to the TT was defined as an improvement in walking speed of 10% or greater compared with baseline. We compared TT response rates between iNPH patients with and without striatal dopaminergic deficit using logistic regression models, with the medical institution (SNUBH, KNUCH) as a stratification variable.
Results: Among 36 patients without striatal dopaminergic deficit, 22 patients (61.11%) exhibited a response after the TT, whereas among 8 patients with striatal dopaminergic deficit, 5 patients (62.5%) exhibited a response after the TT. The response rate after TT was not significantly different between the iNPH patients with and without striatal dopaminergic deficit (odds ratio 0.46; p value = 0.4048).
Discussion: Our findings suggest that gait improvement after a CSF TT in patients with iNPH remains consistent regardless of the presence or absence of reduced striatal DAT uptake. Further research involving a larger cohort is necessary to validate these observations.
期刊介绍:
Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.